Evgen Pharma PLC’s (EVG) Speculative Buy Rating Reiterated at Beaufort Securities
Separately, Northland Securities reissued a buy rating and set a GBX 97 ($1.29) price objective on shares of Evgen Pharma PLC in a research report on Wednesday, October 4th.
Shares of Evgen Pharma PLC (LON:EVG) opened at 18.50 on Thursday. Evgen Pharma PLC has a 52 week low of GBX 15.25 and a 52 week high of GBX 30.25. The firm’s 50-day moving average price is GBX 17.30 and its 200 day moving average price is GBX 18.99. The firm’s market capitalization is GBX 13.56 million.
About Evgen Pharma PLC
Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane.
Receive News & Ratings for Evgen Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.